Skip to main content
. 2018 Feb 16;2(2):282–290. doi: 10.1002/rth2.12076

Table 5.

All DOACs and dabigatran postoperative outcomes pooled incidence analysis

  30‐day thromboembolic % [95% CI; I 2] 30‐day major bleeding % [95% CI; I 2] 30‐day minor bleeding % [95% CI; I 2] 30‐day overall mortality % [95% CI]
Overall 0.41% [0.29‐0.54; 0%] 1.81% [0.84‐3.1; 92.4%] 3.08% [1.02‐6.20; 97.7%] 0.67% [0.29‐1.23]
Dabigatran 0.44% [0.26‐0.68; 0%] 2.56% [0.92‐4.99; 76.9%] 5.15% [2.21‐9.25; 85.2%] 0.74% [0.24‐1.53]

DOAC, Direct Oral Anticoagulant.